Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epoetin alfa for transfusion reduction in orthopedic surgery
NCT00270036Phase 2Completed
- Sponsor
- Johnson & Johnson
- Start
- Apr 1991
- Modality
- Biologic, rProtein (Recombinant Protein)
01
Overview
Phase 2, randomised, double-blind trial of epoetin alfa in anemia (3 arms), sponsored by Johnson & Johnson. Primary endpoints: Transfusion requirements following surgery, Change in hematocrit and 2 more. Started Apr 1991; status: completed.
02
Drugs
epoetin alfa
03
Conditions
anemia
Beyond the preview
Go deeper on NCT00270036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00270036.